Anixa Biosciences Inc (ANIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 10/31
| 01-2021 | 10-2020 | 07-2020 | 04-2020 | 01-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 11,983 | 6,417 | 5,928 | 2,888 | 2,822 |
| Marketable Securities | 2,000 | 2,640 | 3,140 | 2,620 | 2,870 |
| Receivables | N/A | N/A | 6 | 32 | 22 |
| TOTAL | $14,564 | $9,369 | $9,264 | $5,657 | $5,869 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | N/A | 187 | 201 |
| Other Non-Current Assets | 40 | 84 | 98 | 81 | 94 |
| TOTAL | $40 | $84 | $98 | $268 | $295 |
| Total Assets | $14,604 | $9,453 | $9,362 | $5,925 | $6,164 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 512 | 232 | 339 | 171 | 367 |
| Accrued Expenses | 973 | 901 | 816 | 850 | 705 |
| TOTAL | $1,526 | $1,189 | $1,213 | $1,077 | $1,126 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 24 | 17 | 26 | 44 | 65 |
| TOTAL | $N/A | $N/A | $11 | $26 | $41 |
| Total Liabilities | $1,526 | $1,189 | $1,224 | $1,103 | $1,166 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 26,706 | 26,077 | 23,789 | 22,976 | 21,007 |
| Common Shares | 262 | 243 | 237 | 215 | 208 |
| Retained earnings | -194,044 | -191,836 | -189,612 | -187,050 | -184,410 |
| Other shareholders' equity | -521 | -497 | -480 | -465 | -447 |
| TOTAL | $13,079 | $8,264 | $8,138 | $4,822 | $4,998 |
| Total Liabilities And Equity | $14,604 | $9,453 | $9,362 | $5,925 | $6,164 |